Egalet Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
1,920.00
22,830.00
16,964.00
26,136.00
Cost of Goods Sold (COGS) incl. D&A
483.00
-
5,229.00
5,666.00
7,235.00
Gross Income
483.00
-
17,601.00
11,298.00
18,901.00
SG&A Expense
10,670.00
35,780.00
68,717.00
92,321.00
84,341.00
EBIT
11,153.00
34,501.00
51,116.00
81,023.00
65,440.00
Unusual Expense
-
2,635.00
840.00
644.00
13,007.00
Non Operating Income/Expense
190.00
3.00
82.00
795.00
740.00
Interest Expense
8,842.00
7,079.00
8,702.00
13,391.00
18,516.00
Pretax Income
20,185.00
44,212.00
59,515.00
91,693.00
69,359.00
Income Tax
22.00
998.00
1,582.00
1,061.00
-
Consolidated Net Income
20,207.00
43,214.00
57,933.00
90,632.00
69,359.00
Net Income
20,207.00
43,214.00
57,933.00
90,632.00
69,359.00
Net Income After Extraordinaries
20,207.00
43,214.00
57,933.00
90,632.00
69,359.00
Net Income Available to Common
20,207.00
43,214.00
57,933.00
90,632.00
69,359.00
EPS (Basic)
15.64
2.97
2.94
3.70
2.05
Basic Shares Outstanding
1,292.30
14,556.90
19,738.00
24,514.60
33,755.50
EPS (Diluted)
15.64
2.97
2.94
3.70
2.05
Diluted Shares Outstanding
1,292.30
14,556.90
19,738.00
24,514.60
33,755.50
EBITDA
10,670.00
33,860.00
48,102.00
76,905.00
60,378.00
Non-Operating Interest Income
-
-
1,225.00
1,282.00
850.00

About Egalet

View Profile
Address
600 Lee Road
Wayne Pennsylvania 19087
United States
Employees -
Website http://www.egalet.com
Updated 09/14/2018
Egalet Corp. engages in the development, manufacture, and commercialization of innovative treatments for pain and other conditions. The firm offers ARYMO, OXAYDO and SPRIX. Its products contain non-narcotic and abuse-deterrent opioid formulations.